Research Article

Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients

Yingkun Xu, Yang Peng, Meiying Shen, Li Liu, Jinwei Lei, Shun Gao, Yuan Wang, Ailin Lan, Han Li, and Shengchun Liu

Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400042, China

Correspondence should be addressed to Shengchun Liu; liushengchun1968@163.com

Received 15 December 2021; Accepted 5 April 2022; Published 20 April 2022

Academic Editor: Faisal Raza

Copyright © 2022 Yingkun Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study is aimed at exploring the potential mechanism of angiogenesis, a biological process-related gene in breast cancer (BRCA), and constructing a risk model related to the prognosis of BRCA patients. We used multiple bioinformatics databases and multiple bioinformatics analysis methods to complete our exploration in this research. First, we use the RNA-seq transcriptome data in the TCGA database to conduct a preliminary screening of angiogenesis-related genes through univariate Cox curve analysis and then use LASSO regression curve analysis for secondary screening. We successfully established a risk model consisting of seven angiogenesis-related genes in BRCA. The results of ROC curve analysis show that the risk model has good prediction accuracy. We can successfully divide BRCA patients into the high-risk and low-risk groups with significant prognostic differences based on this risk model. In addition, we used angiogenesis-related genes to perform cluster analysis in BRCA patients and successfully divided BRCA patients into three clusters with significant prognostic differences, namely, cluster 1, cluster 2, and cluster 3. Subsequently, we combined the clinical-pathological data for correlation analysis, and there is a significant correlation between the risk model and the patient’s T and stage. Multivariate Cox regression curve analysis showed that the age of BRCA patients and the risk score of the risk model could be used as independent risk factors in the progression of BRCA. In particular, based on this angiogenesis-related risk model, we have drawn a matching nomogram that can predict the 5-, 7-, and 10-year overall survival rates of BRCA patients. Subsequently, we performed a series of pan-cancer analyses of CNV, SNV, OS, methylation, and immune infiltration for this risk model gene and used GDSC data to explore drug sensitivity. Subsequently, to gain insight into the protein expression of these risk model genes in BRCA, we used the immunohistochemical data in the THPA database for verification. The results showed that the protein expressions of IL18, RUNX1, SCG2, and THY1 molecules in BRCA tissues were significantly higher than those in normal breast tissues, while the protein expressions of PF4 and TNFSF12 molecules in BRCA tissues were significantly lower than those in normal breast tissues. Finally, we conducted multiple GSEA analyses to explore the biological pathways these risk model genes can cross in cancer progression. In summary, we believe that this study can provide valuable data and clues for future studies on angiogenesis in BRCA.

1. Introduction

Breast cancer (BRCA) is the most common malignant tumor that seriously endangers women’s physical and mental health [1]. Worldwide, the number and incidence of BRCA have increased rapidly, and it has now surpassed lung cancer to become the world’s largest tumor type [2], although early diagnosis and early treatment nowadays have significantly improved the curative effect of breast cancer [3, 4]. However, postoperative recurrence and metastasis of BRCA are the leading causes of BRCA death, and they have now become the focus of BRCA treatment [5]. Our understanding of the pathogenesis and process of breast cancer is still in its infancy [6]. Therefore, it is necessary to continuously
explore BRCA recurrence and metastasis molecular mechanisms and look for potential intervention targets.

Tumor angiogenesis is when abnormal proliferation, mainly capillary blood vessels, is generated based on original blood vessels, and blood circulation is established in tumor tissues [7]. The structure and function of new capillaries in tumor tissues are very different from normal tissues. Compared with normal blood vessels, tumor neovascularization has the characteristics of an extensive vascular endothelial gap, weak vessel wall, strong vascular permeability, and structural disorder [8]. Angiogenesis plays an essential role in the occurrence, development, invasion, and metastasis of BRCA, and it is also an independent prognostic factor of BRCA patients [9]. BRCA is a solid tumor, and its occurrence and development depend on angiogenesis [10]. Normal breast tissue has a loose structure and abundant lymph and blood supply. Therefore, new blood vessels are easily formed, and tumor metastasis occurs during the development of BRCA. There will be various biological and morphological changes in breast hyperplasia and precancerous lesions, including changes in the tumor microenvironment [11], among which tumor angiogenesis is the earliest [12].

Precision medicine is a new medical model formed under the background of the rapid development of modern gene sequencing and the fusion of bioinformatics and big data based on the Human Genome Project [13]. With the rise of precision medicine on a global scale, the precise diagnosis and treatment of BRCA are imminent, and traditional histopathological classification can no longer meet the needs of current BRCA research and treatment [14]. Traditional histopathological classification has been unable to meet BRCA research and treatment [15, 16]. The correct application of tumor molecular classification is the basic premise of contemporary precision medicine [17]. The molecular and histopathological classifications of BRCA can be better integrated so that clinicians can formulate effective and individualized treatment plans for BRCA patients more scientifically. Therefore, in this study, while exploring the biological significance of angiogenesis-related genes in BRCA, we used these genes to perform cluster analysis in BRCA. The results show that we successfully divided BRCA patients into three clusters with significant prognostic differences, namely cluster1, cluster2, and cluster3. We believe that these classification data will help the precise treatment of different BRCA patients in the future. In addition, this study used multiple bioinformatics databases and various bioinformatics methods to conduct in-depth research on angiogenesis-related genes in BRCA. We believe that this research can provide detailed and reliable data support for future scientific research and clinical treatment.

2. Materials and Methods

2.1. Data Acquisition. The Cancer Genome Atlas (TCGA) research network has performed a high-throughput analysis of many human tumors to find molecular aberrations at the nucleic acid, protein, and epigenetic levels [18]. In November 2021, we downloaded the gene expression, variation, and clinical information of 1,098 BRCA samples through the GDC (Genomic Data Commons) official portal of the TCGA database (https://portal.gdc.cancer.gov/). To find genes related to angiogenesis, we collected 48 angiogenesis-related genes through the GSEA (Gene Set Enrichment Analysis) database (https://www.gsea-msigdb.org/gsea/index.jsp) [19, 20]. The standard name of this gene set is ANGIOGENESIS, and the systematic name is M14493.

2.2. Data Processing and Analysis. This study used Perl and R language to download BRCA RNA-seq transcriptome data and clinical-pathological information from the TCGA database to process and draw graphs. First, we used the RNA-seq transcriptome data of the BRCA dataset in the TCGA database to use the “pheatmap” expansion package to draw a heat map of the expression of angiogenesis-related genes and use the “limma” expansion package to analyze the differences in the expression of angiogenesis-related genes. STRING can be used to predict the protein-protein interaction (PPI) network, which is an online database platform (https://cn.string-db.org/) [21, 22]. To explore the relationship between these angiogenesis-related molecules, we used the protein interaction data in the STRING database to draw a PPI network. After that, we performed a univariate Cox regression curve analysis of these angiogenesis-related molecules in BRCA to show the relationship between these molecules and the progress of BRCA. Subsequently, we used cluster analysis to classify BRCA patients into three clusters with significant prognostic differences. Then, we used the “glmnet” and “survival” expansion packages based on the R language to perform LASSO regression curve analysis and draw the corresponding survival curve. To verify the prediction accuracy of the risk model, we used the “survivalROC” extension package to perform ROC curve analysis. The risk model comprises seven genes, BTG1, IL18, PF4, RUNX1, SCG2, THY1, and TNFSF12. Subsequently, combined with clinicopathological data, we analyzed the correlation between the risk model and the pathological characteristics of BRCA patients. In particular, we performed univariate and multivariate Cox regression curve analyses through the “survival” and “forestplot” expansion packages. Subsequently, to facilitate clinical diagnosis and treatment in the future, we integrated various risk factors and used the “rms” expansion package to draw the corresponding nomogram. Finally, to explore the biological pathways that the risk model gene can affect in BRCA, we used the “plyr,” “ggplot2,” “grid,” and “gridExtra” expansion packages to perform a multi-GSEA analysis.

2.3. GEPIA Website. Gene Expression Profiling Interactive Analysis (GEPIA) is a website developed by Peking University, which can analyze the RNA-seq expression data of 9736 tumor samples and 8587 normal samples in the TCGA and GTEx projects (http://gepia.cancer-pku.cn/) [23, 24]. In this study, we used the online analysis tool on the GEPIA website to perform pan-cancer analysis on CNV and SNV of angiogenesis-related risk model genes. The results were displayed in the form of heat maps.
2.4. GSCA Website. Gene Set Cancer Analysis (GSCA) is a cross-over comprehensive cancer analysis database that integrates single gene analysis, multiple gene analysis, immune infiltration analysis, mutation analysis, and drug sensitivity analysis. It contains 33 types of cancer data from TCGA, ImmuCellAI, and GDSC (http://bioinfo.life.hust.edu.cn/GSCA/#/) [25, 26]. This study combined the angiogenesis-related risk model gene mRNA expression data and drug sensitivity data to perform a Pearson correlation analysis to obtain the correlation between the risk model gene mRNA expression and the drug IC50. FDR adjusts the P value.

2.5. TIMER Database. Tumor Immune Estimation Resource (TIMER) is a database that supports the analysis of tumor-infiltrating immune cell components (http://cistrome.org/TIMER/) [27, 28]. When we input the gene expression profile data of tumor samples, we can predict the composition of immune cells infiltrated in each tumor sample and support the analysis of the following six types of immune cells: B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil, and dendritic cell. In this study, we used angiogenesis-related risk model gene mRNA expression data, combined with immune cell infiltration data in the TIMER database, to explore the relationship between risk model gene mRNA expression and immune cell infiltration in BRCA, and used R The language “pheatmap” expansion pack draws the corresponding heat map.

2.6. The Human Protein Atlas Database. The Human Protein Atlas (THPA) database provides information on the tissue and cell distribution of all 24,000 human proteins and is free for public inquiries (https://www.proteinatlas.org/). The Swedish Knut & Alice Wallenberg Foundation, which created this database, uses special antibodies and immunohistochemical techniques to examine each protein in 48 normal human tissues, 20 types of tumor tissues, 47 cell lines, and 12 types of blood cells. The distribution and expression of the results are read and indexed by professionals [29–31]. In this study, we used the immunohistochemistry data in the THPA database to explore the expression of angiogenesis-related risk model genes in BRCA tissues and normal breast tissues.

3. Results

3.1. The Expression of Angiogenesis-Related Genes in BRCA and the Interaction of the Encoded Proteins. To make our research easier to understand, we present this research’s main analysis methods and steps in a flowchart (Figure 1). To understand the expression of angiogenesis-related genes in BRCA, we used the mRNA expression data in the TCGA database to draw a heat map. We find that most angiogenesis-related genes have significant differences in expression between BRCA tissues and normal breast tissues through the heat map. Among them, the expression of star molecules VEGFA, SPHK1, and SCG2 in BRCA samples was significantly higher than that in the control group. The expressions of NOTCH4, STAB1, and SERPINF1 in BRCA samples were significantly lower than those in the control group (Figure 2(a)). The results of univariate Cox analysis showed that SCG2, PF4, and THY1 played risk factors in BRCA progression, while BTG1, TNFSF12, RUNX1, and IL18 played protective factors in BRCA progression (Figure 2(b)). Then by consulting protein-protein interaction networks, we can find a strong correlation between the PF4 molecule and the CXCL8 molecule (Figure 2C). These molecules are potential targets for future BRCA prevention and control.
Figure 2: Continued.
| Gene  | Hazard Ratio | 95% CI       | p-value |
|-------|--------------|--------------|---------|
| CXCL8 | 0.990        | (0.959 - 1.022) | 0.531   |
| NPR1  | 0.960        | (0.940 - 0.980) | 0.002   |
| SCG2  | 1.045        | (1.016 - 1.076) | 0.005   |
| BTG1  | 0.966        | (0.815 - 1.144) | 0.022   |
| C14K4 | 0.978        | (0.953 - 1.002) | 0.054   |
| YNFR12| 0.983        | (0.968 - 0.999) | 0.006   |
| AGG1  | 0.982        | (0.962 - 1.002) | 0.023   |
| NCL   | 0.981        | (0.960 - 1.002) | 0.034   |
| NFI   | 1.042        | (1.000 - 1.091) | 0.076   |
| PKR   | 0.980        | (0.963 - 1.007) | 0.011   |
| ENSR  | 0.981        | (0.963 - 1.000) | 0.026   |
| COX2  | 1.053        | (1.030 - 1.080) | 0.009   |
| THY1  | 1.003        | (1.001 - 1.005) | 0.021   |
| FOXO4 | 0.983        | (0.975 - 0.990) | 0.009   |
| MET26 | 0.986        | (0.965 - 1.007) | 0.034   |
| S100A5| 0.982        | (0.964 - 0.999) | 0.007   |
| COL2A1| 0.988        | (0.969 - 1.007) | 0.024   |
| TNFR2 | 0.989        | (0.972 - 1.007) | 0.009   |
| ACVRL1| 1.000        | (0.997 - 1.004) | 0.045   |
| ROBO4 | 0.983        | (0.968 - 0.998) | 0.009   |
| ACVR1 | 1.003        | (0.990 - 1.016) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |
| ACVR1 | 1.000        | (0.990 - 1.010) | 0.047   |

**Figure 2:** Continued.
3.2. Use Angiogenesis-Related Genes to Perform Cluster Analysis in BRCA. In recent decades of cancer research, scientific researchers generally consider cluster analysis to provide theoretical support for precise cancer treatment. In this study, based on the TCGA database, we used the differences in the expression of these angiogenesis-related genes in BRCA patients to perform a cluster analysis. When $k = 3$, the generated consensus matrix shows a good clustering effect, and the result is verified (Figures 3(a)–3(c)). Subsequently, we developed the survival curve of BRCA patients based on the cluster analysis results ($P = 0.027$) (Figure 3(d)). Therefore, we believe that this new type of cluster classification is beneficial to future accurate clinical diagnosis and treatment.

3.3. Use Angiogenesis-Related Genes to Perform LASSO Regression Analysis in BRCA. To use these angiogenesis-related genes to establish a risk model in BRCA, we first performed a LASSO regression curve analysis on these angiogenesis-related genes and verified the availability of the results (Figures 4(a) and 4(b)). We successfully constructed a risk model consisting of 7 genes, including BTG1, IL18, PF4, RUNX1, SCG2, THY1, and TNFSF12. Based on this risk model, we divided BRCA patients into the high-risk and low-risk groups and drew the corresponding survival curves. The results of the survival curve show that the overall survival rate of BRCA patients in the high-risk group is significantly lower than that of BRCA patients in the low-risk group ($P = 9.307e - 05$) (Figure 4(c)). Finally, based on the risk model, our ROC curve analysis showed that the 7-year AUC value is 0.711 (Figure 4(d)), which implies that the risk prediction model is highly accurate.

3.4. Based on the Constructed Risk Model, Explore the Clinical Relevance and Draw the Nomogram. The relationship between the risk model and clinicopathological characteristics has always been an essential direction of concern. To explore the correlation between the risk model and
Clinicopathological features, we conducted a correlation analysis and displayed it in the form of a heat map (Figure 5(a)). The results show that the risk model strongly correlates with the two clinicopathological characteristics of T and stage of BRCA patients.

Subsequently, we performed univariate Cox regression analysis and multivariate Cox regression analysis based on the risk model (Figures 5(b) and 5(c)). We found that the age of BRCA patients and the risk score of this risk model are independent risk factors for BRCA patients. Finally, based on the risk model, we draw a nomogram that can predict the overall survival rate of BRCA patients at 5, 7, and 10 years (Figure 5(d)).

3.5. Based on the Constructed Risk Model, Pan-Cancer Analysis and Sensitivity Analysis of Multiple Anticancer
Drugs Were Carried Out. Although many studies have explored the mutations of multiple risk model genes in various cancers, the mutations in multiple cancers have not been well summarized. In addition, modern scientific research has confirmed that gene mutations may affect the overall survival rate of cancer patients [32, 33]. Therefore, this study explored and summarized the CNV, SNV, and OS of these seven risk model genes in pan-cancer. By observing the heat map showing the CNV situation, we found that RUNX1, SCG2, and BTG1 have high heterozygous amplification in various cancers, including ACC, TGCT, and UCS. However, TNFSF2, THY, and IL8 have higher heterozygous deletions in multiple cancers, including BRCA, TGCT, and SKCM (Figure 6(a)).

In the results of subsequent SNV analysis, we found that RUNX1 has a higher mutation frequency in BRCA, UCEC, and BLCA, and these seven risk model genes have varying degrees of mutation frequency in UCEC and SKCM (Figure 6(b)). In analyzing the survival of these seven risk model genes in pan-cancer, we found that most genes significantly correlate with the survival of BRCA, KIRC, KIRP, and UVM patients. THY1, SCG2, and RUNX1 play risk factors in various cancer types (Figure 6(c)).

In recent years, cancer research around methylation has emerged one after another [34–36]. Therefore, we conducted a differential analysis of methylation in pan-cancer for these seven risk model genes. RUNX1 has a high methylation status in UCEC, LUSC, and LUAD, and IL18 has a low methylation status in BRCA, BLCA, and KIRC (Figure 6(d)). Then based on the ImmuCellAI database, we found that this risk model is negatively correlated with the degree of immune cell infiltration such as neutrophil, Th17, and CD8 naïve and positively correlated with the degree of immune cell infiltration such as Tfh, NK, and macrophage in most cancer types (Figure 6(e)). Subsequently, to discover...
Figure 5: Continued.
candidate biomarkers and valuable small molecule drugs, we used the GDSC database to closely integrate genes with clinical information and more than 750 small molecule drugs, which provided help for future experimental design and further clinical trials. The results show that the expression of IL18 and RUNX1 genes is related to the sensitivity of a variety of mainstream anticancer drugs (Figure 6(f)). We can use this correlation to provide patients with more efficient treatment options in the future.

3.6. For the Risk Model Genes, Explore Their Protein Expression Levels in BRCA and Normal Tissues. To verify our previous results, we used the immunohistochemical data in the THPA database to explore the expression of these risk model genes between BRCA tissue and normal breast tissue. Here, we show the immunohistochemical images of IL18, PF4, RUNX1, SCG2, THY1, and TNFSF12 (Figures 7(a)–7(f)). These immunohistochemical results showed that the expression of IL18, RUNX1, SCG2, and THY1 molecules in normal breast tissues was significantly lower than that in BRCA tissues, while PF4 and TNFSF12 molecules showed the opposite expression. This evidence corroborates our previous findings, and our results have higher credibility.

3.7. For This Risk Model Genes, GSEA Analysis Was Performed in BRCA. To deeply explore the potential biological role of these risk model genes in cancer progression, based on the TCGA database, we conducted multiple GESA analyses in BRCA for these seven risk model genes. The results show that these seven risk model genes are related to various cancer pathways in BRCA (Figures 8(a)–8(g)). For example, BTG1 and IL18 are related to abnormal activation of JAK-STAT signaling pathway. RUNX1 is related to the abnormal activation of TGF-beta signaling pathway. THY1 and TNFSF12 are related to abnormal inhibition of CELL CYCLE. Therefore, we believe that these detailed data

| p-value | Hazard ratio |
|---------|-------------|
| Age     | <0.001      | 1.031 (1.016 – 1.046) |
| Gender  | 0.611       | 0.597 (0.082 – 4.341)  |
| Stage   | 0.059       | 1.638 (0.981 – 2.736)  |
| T       | 0.580       | 0.917 (0.674 – 1.247)  |
| M       | 0.231       | 1.671 (0.721 – 3.873)  |
| N       | 0.174       | 1.225 (0.914 – 1.641)  |
| Riskscore | <0.001   | 1.214 (1.120 – 1.315) |

(c)

| Points |
|--------|
| Age    |
| Stage  |
| Riskscore |
| Total points |
| 5-year survival |
| 7-year survival |
| 10-year survival |

(d)

Figure 5: Based on the constructed risk model, explore the clinical relevance and draw the nomogram. (a) The heat map was used to show the correlation between the angiogenesis-related risk model and the clinicopathological characteristics of BRCA patients. (b) Univariate Cox regression analysis. (c) Multivariate Cox regression analysis. (d) The nomogram was used to predict the 5-, 7-, and 10-year overall survival rates of BRCA patients. *P < 0.05, **P < 0.01, and ***P < 0.001.
Copy number variation across cancer types

Single nucleotide variant across cancer types

Survival landscape across cancer types

Figure 6: Continued.
Figure 6: Continued.
can provide important clues for future exploration of the mechanism of these seven risk model genes in BRCA.

4. Discussion

In the research process of human anticancer progress, with the deepening of research, researchers gradually realized that there are many differences between the same tumors; the most fundamental difference is at the level of biomolecules. The concept of tumor molecular classification was first proposed by the National Cancer Institute in 1999. A new tumor classification system uses molecular analysis techniques to classify tumors based on molecular characteristics. In 2000, Perou et al. first proposed the molecular classification of BRCA, dividing BRCA into two groups: estrogen receptor (ER) positive and negative. The ER-positive group is called luminal type breast cancer [37]. The ER-negative group is divided into human epidermal growth factor receptor-2 (HER2) overexpression type, basal cell-like type, and normal breast-like type. Subsequently, many scholars have further confirmed and enriched the BRCA molecular typing theory through many studies and made significant progress [38–40]. Similarly, in this study, we performed a cluster analysis in BRCA using angiogenesis-related genes and could classify BRCA patients into subgroups with differences in survival. We believe this will be very helpful for precision medicine in the future.

In addition, in the past few decades, the construction of risk models around cancer-related biological processes or signaling pathway-related genes has succeeded [41–43]. Therefore, inspired by previous research, we used angiogenesis-related genes to construct a risk model for BRCA. Based on this model, we can divide BRCA patients into two groups with different overall survival rates: a high-risk group and a low-risk group. With the successful application of more and more prognostic models in clinical practice, we believe that this angiogenesis-related predictive risk model can accurately identify the risk differences of different patients [44–46]. Clinicians can use this risk difference to differentiate treatment and treatment of patients. For example, for patients in the high-risk group, the frequency of clinical therapy, testing and review can be increased, which is more conducive to patient survival.

The BTG1 gene was first identified from the chronic B lymphocytic leukemia chromosome and then isolated from lymphoblasts [47, 48]. It is located on chromosome 12q22.
and can regulate cell proliferation by regulating the cell cycle [49]. Previous research reports have found that the BTG1 gene has abnormally low expression in breast cancer, gastric cancer, non-small-cell lung cancer, and pancreatic cancer tissues compared to normal tissues and is related to multiple clinical features such as lymph node metastasis, TNM (Tumor Node Metastasis) stage, and prognosis [50–53]. This shows that the BTG1 gene plays a similar role to tumor suppressor genes in the occurrence and development of various cancers and may be a potential tumor biomarker and therapeutic target. IL-8 is a proinflammatory cytokine, which plays a complex role in regulating tumor microenvironment [54] and may lead to tumor cell proliferation, survival, and chemoresistance of malignant diseases [55, 56]. High serum IL-8 expression is now associated with poor prognosis of patients with various tumors (including BRCA) [57, 58]. In BRCA, patients with high serum IL-8 levels have a worse prognosis than patients with low IL-8 levels [59, 60].

Figure 7: For the risk model genes, explore their protein expression levels in BRCA and normal tissues. (a) IL18, (b) PF4, (c) RUNX1, (d) SCG2, (e) THY1, and (f) TNFSF12.
Figure 8: Continued.
Figure 8: Continued.
SCG2

Enrichment score

HIGH EXPRESSION<---LOW EXPRESSION

KEGG_BASE_EXCISION_REPAIR
KEGG_CALCIUM_SIGNALING_PATHWAY
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
KEGG_ECM_RECEPTOR_INTERACTION
KEGG_FOCAL_ADHESION
KEGG_HOMOLOGOUS_RECOMBINATION
KEGG_HUNTINGTONS_DISEASE
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION
KEGG_PYRIMIDINE_METABOLISM
KEGG_SPLICEOSOME

THY1

Enrichment score

HIGH EXPRESSION<---LOW EXPRESSION

KEGG_CELL_CYCLE
KEGG_CYSSTEINE_AND_METHIONINE_METABOLISM
KEGG_DILATED_CARDIOMYOPATHY
KEGG_ECM_RECEPTOR_INTERACTION
KEGG_FOCAL_ADHESION
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE
KEGG_LEU_KOCYTE_TRANSENDOTHELIAL_MIGRATION
KEGG_NUCLEOTIDE_EXCISION_REPAIR
KEGG_OOCYTE_MEROSIS
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS

Figure 8: Continued.
In previous studies, researchers have determined that PF4 can be used as an antiangiogenic factor to inhibit endothelial cell proliferation, migration, and angiogenesis in a variety of in vitro and in vivo models of cancer [61–64]. Among them, in the in vivo model of BRCA, upregulating PF4 can increase the expression of proapoptotic protein and downregulate the expression of antiapoptotic protein, thereby promoting cell apoptosis and achieving the effect of reducing tumor volume [65]. RUNX1 is a member of the RUNX transcription factor family. It is located at 21q22 and contains 138 amino acid Runt homologous functional regions. Existing studies have found that RUNX1 exerts a tumor suppressor effect in liver cancer and gastric cancer [66, 67], but in non-small-cell lung cancer and endometrial cancer [68, 69]. It plays a role in promoting cancer in cancer and in suppressing or promoting cancer in different subtypes of BRCA [70, 71]. As an essential transcription factor, RUNX1 mainly acts by directly or indirectly regulating signal transduction pathways such as TGFβ, WNT, and BMP [72]. However, the three genes SCG2, THY1, and TNFSF12 have not been studied in BRCA. In the future, we need to conduct in-depth exploration to determine the potential role of these three genes in BRCA.

5. Conclusion

In previous studies, researchers have determined that PF4 can be used as an antiangiogenic factor to inhibit endothelial cell proliferation, migration, and angiogenesis in a variety of in vitro and in vivo models of cancer [61–64]. Among them, in the in vivo model of BRCA, upregulating PF4 can increase the expression of proapoptotic protein and downregulate the expression of antiapoptotic protein, thereby promoting cell apoptosis and achieving the effect of reducing tumor volume [65]. RUNX1 is a member of the RUNX transcription factor family. It is located at 21q22 and contains 138 amino acid Runt homologous functional regions. Existing studies have found that RUNX1 exerts a tumor suppressor effect in liver cancer and gastric cancer [66, 67], but in non-small-cell lung cancer and endometrial cancer [68, 69]. It plays a role in promoting cancer in cancer and in suppressing or promoting cancer in different subtypes of BRCA [70, 71]. As an essential transcription factor, RUNX1 mainly acts by directly or indirectly regulating signal transduction pathways such as TGFβ, WNT, and BMP [72]. However, the three genes SCG2, THY1, and TNFSF12 have not been studied in BRCA. In the future, we need to conduct in-depth exploration to determine the potential role of these three genes in BRCA. LASSO regression analysis, pan-cancer analysis, and multi-GSEA analysis in BRCA and successfully constructed a predictive risk model consisting of seven genes BTG1, IL18, PF4, RUNX1, SCG2, THY1, and TNFSF12, although this study still has some shortcomings. For example, it has not been supported by single-center or multicenter clinical data. However, we believe that this research will provide many valuable clues for future scientific research. We will continue to explore the potential mechanisms of these risk model genes in BRCA progression in future scientific explorations.

Abbreviations

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| BRCA         | Breast cancer                                    |
| TCGA         | The Cancer Genome Atlas                          |
| GDC          | Genomic Data Commons                             |
| GEPIA        | Gene Expression Profiling Interactive Analysis   |
| GSCA         | Gene Set Cancer Analysis                         |
| TIMER        | Tumor Immune Estimation Resource                 |
| THPA         | The Human Protein Atlas                          |
| ImmuCellAI   | Immune Cell Abundance Identifier                 |
| GDSC         | Genomics of Drug Sensitivity in Cancer           |
| LASSO        | Least Absolute Shrinkage and Selection Operator  |
| GSEA         | Gene Set Enrichment Analysis                     |
| BTG1         | BTG Antiproliferation Factor 1                   |
| IL18         | Interleukin 18                                   |
| PF4          | Platelet Factor 4                                |

Figure 8: For this risk model genes, GSEA analysis was performed in BRCA. (a) BTG1, (b) IL18, (c) PF4, (d) RUNX1, (e) SCG2, (f) THY1, and (g) TNFSF12.
RUNX1: RUNX Family Transcription Factor 1
SCG2: Secretogranin II
THY1: Thy-1 Cell Surface Antigen
TNFSF12: TNF Superfamily Member 12.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Shengchun Liu and Yingkun Xu designed the research methods and analyzed the data. Yang Peng, Meiying Shen, and Li Liu participated in data collection. Yingkun Xu, Shun Gao, and Yuan Wang drafted the manuscript. Jinwei Lei, Ailin Lan, and Han Li revised the manuscript. All authors approved the version to be released and agreed to be responsible for all aspects of the work.

Acknowledgments

This research was funded by the National Natural Science Foundation of China (Grant nos. 81772979 and 81472658) and the Key Research and Development Project of Chongqing’s Technology Innovation and Application Development Special Big Health Field (Grant no. CSTC2021jscx-gksb-N0027). We thank the Cancer Genome Atlas (TCGA) for providing publicly available data. In addition, Yingkun Xu is particularly grateful to Jiayi Li of Hanyang University for her assistance in the progress of this research.

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: a Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
[3] S. S. Coughlin and D. U. Ekwueme, “Breast cancer as a global health concern,” Cancer Epidemiology, vol. 33, no. 5, pp. 315–318, 2009.
[4] N. Biglia, M. D’Alonzo, L. G. Sgro, N. Tomasi Cont, V. Bounous, and E. Robba, "Breast cancer treatment in mutation carriers: surgical treatment", Minerva Ginecologica, vol. 68, no. 5, pp. 548–556, 2016.
[5] M. Malvezzi, G. Carioli, P. Bertuccio et al., "European cancer mortality predictions for the year 2019 with focus on breast cancer," Annals of Oncology, vol. 30, no. 5, pp. 781–787, 2019.
[6] M. Fahad Ullah, "Breast cancer: current perspectives on the disease status," Advances in Experimental Medicine and Biology, vol. 1152, pp. 51–64, 2019.
[7] F. H. Al-Ostoot, S. Salah, H. A. Khamees, and S. A. Khanum, "Tumor angiogenesis: current challenges and therapeutic opportunities," Cancer Treatment and Research Communications, vol. 28, p. 100422, 2021.
[8] D. Parmar and M. Apte, “Angiopoietin inhibitors: a review on targeting tumor angiogenesis,” European Journal of Pharmacology, vol. 899, p. 174021, 2021.
[9] S. C. Reuben, A. Gopalan, D. M. Petit, and A. Bishayee, “Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer,” Molecular Nutrition & Food Research, vol. 56, no. 1, pp. 14–29, 2012.
[10] J. M. Castañeda-Gill and J. K. Vishwanatha, "Antiangiogenic mechanisms and factors in breast cancer treatment," Journal of Carcinogenesis, vol. 15, no. 1, p. 1, 2016.
[11] J. Choi, J. Gyamfi, H. Jang, and J. S. Koo, “The role of tumor-associated macrophage in breast cancer biology,” Histology and Histopathology, vol. 33, no. 2, pp. 133–145, 2018.
[12] E. Keyhani, A. Muhammadnejad, F. Behjati et al., “Angiogenesis markers in breast cancer - potentially useful tools for priority setting of anti-angiogenic agents,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 12, pp. 7651–7656, 2013.
[13] G. Middleton, H. Robbins, F. Andre, and C. Swanton, "Antiangiogenic therapy in breast cancer: implications for precision medicine," Annals of Oncology, vol. 33, no. 2, pp. 143–157, 2022.
[14] S. E. Jackson and J. D. Chester, "Personalised cancer medicine," International Journal of Cancer, vol. 137, no. 2, pp. 262–266, 2015.
[15] I. Greenwald, N. Zaza, S. Das, and B. D. Li, "Precision medicine and targeted therapies in breast cancer," Surgical Oncology Clinics of North America, vol. 29, no. 1, pp. 51–62, 2020.
[16] J. Yan, Z. Liu, S. Du, J. Li, L. Ma, and L. Li, "Diagnosis and treatment of breast cancer in the precision medicine era," Methods in Molecular Biology, vol. 2204, pp. 53–61, 2020.
[17] A. M. Tsimberidou, E. Fountzilas, M. Nikanjam, and R. Kurzrock, "Review of precision cancer medicine: evolution of the treatment paradigm," Cancer Treatment Reviews, vol. 86, p. 102019, 2020.
[18] J. N. Weinstein, E. A. Colisson, G. B. Mills et al., "The Cancer Genome Atlas Pan-Cancer analysis project," Nature Genetics, vol. 45, no. 10, pp. 1113–1120, 2013.
[19] A. Subramanian, P. Tamayo, V. K. Mootha et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545–15550, 2005.
[20] V. K. Mootha, C. M. Lindgren, K. F. Eriksson et al., "PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes," Nature Genetics, vol. 34, no. 3, pp. 267–273, 2003.
[21] D. Szklarczyk, A. L. Gable, K. C. Nastou et al., "The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets," Nucleic Acids Research, vol. 49, no. D1, pp. D605–D612, 2021.
[22] D. Szklarczyk, A. L. Gable, D. Lyon et al., "STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets," Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.
[23] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, "GEPIA: a web server for cancer and normal gene expression profiling
and interactive analyses,” *Nucleic Acids Research*, vol. 45, no. W1, pp. W98–w102, 2017.
24. Z. Tang, B. Kang, C. Li, T. Chen, and Z. Zhang, “GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis,” *Nucleic Acids Research*, vol. 47, no. W1, pp. W556–w560, 2019.
25. Y. R. Miao, M. Xia, M. Luo, T. Luo, M. Yang, and A. Y. Guo, “ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction,” *Bioinformatics*, vol. 38, no. 3, pp. 785–791, 2022.
26. Y. R. Miao, Q. Zhang, Q. Lei et al., “ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy,” *Advanced Science*, vol. 7, no. 7, p. 1902880, 2020.
27. T. Li, J. Fan, B. Wang et al., “TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells,” *Cancer Research*, vol. 77, no. 21, pp. e108–e110, 2017.
28. B. Li, E. Severson, J. C. Pignon et al., “Comprehensive analyses of tumor immunity: implications for cancer immunotherapy,” *Genome Biology*, vol. 17, no. 1, p. 174, 2016.
29. M. Uhlen, L. Fagerberg, B. M. Hallström et al., “Proteomics. Tissue-based map of the human proteome,” *Science*, vol. 347, no. 6220, p. 1260419, 2015.
30. P. J. Thul, L. Åkesson, M. Wikin et al., “A subcellular map of the human proteome,” *Science*, vol. 356, no. 6340, 2017.
31. M. Uhlen, C. Zhang, S. Lee et al., “A pathology atlas of the human cancer transcriptome,” *Science*, vol. 357, no. 6352, 2017.
32. D. Yang, S. Khan, Y. Sun et al., “Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer,” *JAMA Oncology*, vol. 3, no. 14, pp. 1557–1565, 2011.
33. K. H. Metzler, T. Herold, M. Rothenberg-Thurley et al., “Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia,” *Blood*, vol. 128, no. 5, pp. 686–698, 2016.
34. C. Koelsche, D. Schrimpf, D. Stichel et al., “Sercoma classification by DNA methylation profiling,” *Nature Communications*, vol. 12, no. 1, p. 498, 2021.
35. J. Dejaeger, L. Solie, Z. Hunin et al., “DNA methylation based glioblastoma subclassification is related to tumor T-cell infiltration and patient survival,” *Neuro-Oncology*, vol. 23, no. 2, pp. 240–250, 2021.
36. K. Wang, W. Huang, R. Chen et al., “Di-methylation of CD147-K234 promotes the progression of NSCLC by enhancing lactate export,” *Cell Metabolism*, vol. 33, no. 1, pp. 160–173.e6, 2021.
37. C. M. Perou, T. Sørlie, M. B. Eisen et al., “Molecular portraits of human breast tumors,” *Nature*, vol. 406, no. 6797, pp. 747–752, 2000.
38. T. O. Nielsen, F. D. Hsu, K. Jensen et al., “Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma,” *Clinical Cancer Research*, vol. 10, no. 16, pp. 5367–5374, 2004.
39. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study,” *JAMA*, vol. 295, no. 21, pp. 2492–2502, 2006.
40. M. C. Cheang, S. K. Chia, D. Voduc et al., “Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer,” *Journal of the National Cancer Institute*, vol. 101, no. 10, pp. 736–750, 2009.
41. G. Wu, Y. Xu, C. Han et al., “Identification of a prognostic risk signature of kidney renal clear cell carcinoma based on regulating the immune response pathway exploration,” *Journal of Oncology*, vol. 2020, Article ID 6657013, 8 pages, 2020.
42. X. Che, X. Qi, Y. Xu, Q. Wang, and G. Wu, “Using genomic and transcriptome analyses to identify the role of the oxidative stress pathway in renal clear cell carcinoma and its potential therapeutic significance,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 5561124, 38 pages, 2021.
43. X. Qi, X. Lv, X. Wang et al., “A new survival model based on cholesterol biosynthesis-related genes for prognostic prediction in clear cell renal cell carcinoma,” *BioMed Research International*, vol. 2021, Article ID 9972968, 15 pages, 2021.
44. B. Li, Y. Cui, M. Diehn, and R. Li, “Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer,” *JAMA Oncology*, vol. 3, no. 11, pp. 1529–1537, 2017.
45. L. Marisa, A. de Reyniés, A. Duval et al., “Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value,” *PLoS Medicine*, vol. 10, no. 5, article e1001453, 2013.
46. E. C. Smyth, G. Nyamundanda, D. Cunningham et al., “A seven-gene signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial,” *Annals of Oncology*, vol. 29, no. 12, pp. 2356–2362, 2018.
47. A. V. Moorman, C. Schwab, H. M. Ensor et al., “IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia,” *Journal of Clinical Oncology*, vol. 30, no. 25, pp. 3100–3108, 2012.
48. L. Yan, N. Ping, M. Zhu et al., “Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification,” *Haematologica*, vol. 97, no. 11, pp. 1708–1712, 2012.
49. J. P. Rouault, R. Rimokh, C. Tessa et al., “BTG1, a member of a new family of antiproliferative genes,” *The EMBO Journal*, vol. 11, no. 4, pp. 1663–1670, 1992.
50. Y. Huang, J. Zheng, T. Tan et al., “BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis,” *The International Journal of Biological Markers*, vol. 33, no. 2, pp. 189–194, 2018.
51. S. H. Sheng, C. M. Zhao, and G. G. Sun, “BTG1 expression correlates with the pathogenesis and progression of breast carcinomas,” *Tumour Biology*, vol. 35, no. 4, pp. 3317–3326, 2014.
52. G. G. Sun, Y. F. Lu, Y. J. Cheng, and W. N. Hu, “The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis,” *Tumour Biology*, vol. 35, no. 4, pp. 2949–2957, 2014.
53. H. C. Zheng, J. Li, D. F. Shen et al., “BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy,” *Oncotarget*, vol. 6, no. 23, pp. 19685–19705, 2015.
54. D. J. Waugh and C. Wilson, “The interleukin-8 pathway in cancer,” *Clinical Cancer Research*, vol. 14, no. 21, pp. 6735–6741, 2008.
55. N. Shao, L. H. Chen, R. Y. Ye, Y. Lin, and S. M. Wang, “The depletion of interleukin-8 causes cell cycle arrest and increases the efficacy of docetaxel in breast cancer cells,” *Biochemical
and Biophysical Research Communications, vol. 431, no. 3, pp. 535–541, 2013.

[56] X. J. Li, L. X. Peng, J. Y. Shao et al., “As an independent unfavorable prognostic factor, IL-8 promotes metastasis of naso-pharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling,” Carcinogenesis, vol. 33, no. 7, pp. 1302–1309, 2012.

[57] I. H. Benoy, R. Salgado, P. Van Dam et al., “Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival,” Clinical Cancer Research, vol. 10, no. 21, pp. 7157–7162, 2004.

[58] Y. Chen, M. Shi, G. Z. Yu et al., “Interleukin-8, a promising predictor for prognosis of pancreatic cancer,” World Journal of Gastroenterology, vol. 18, no. 10, pp. 1123–1129, 2012.

[59] J. Milovanović, N. Todorović-Raković, and M. Radulovic, ”Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer,” Cytokine, vol. 118, pp. 93–98, 2019.

[60] L. Tiainen, M. Hämäläinen, T. Luukkaala et al., “Low plasma IL-8 levels during chemotherapy are predictive of excellent long-term survival in metastatic breast cancer,” Clinical Breast Cancer, vol. 19, no. 4, pp. e522–e533, 2019.

[61] S. Aidoudi and A. Bikfalvi, ”Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis,” Thrombosis and Haemostasis, vol. 104, no. 5, pp. 941–948, 2010.

[62] D. F. Quail and J. A. Joyce, “Microenvironmental regulation of tumor progression and metastasis,” Nature Medicine, vol. 19, no. 11, pp. 1423–1437, 2013.

[63] R. J. Sharpe, H. R. Byers, C. F. Scott, S. I. Bauer, and T. E. Maione, ”Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4,” Journal of the National Cancer Institute, vol. 82, no. 10, pp. 848–853, 1990.

[64] P. Liang, S. H. Cheng, C. K. Cheng et al., ”Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma,” Haematologica, vol. 98, no. 2, pp. 288–295, 2013.

[65] T. A. A.-T. D. Sin, S. H. Shamsuddin, F. M. Idris, W. N. A. W. Mansor, M. I. A. Jalal, and H. Jaafar, ”Rapamycin and PF4 induce apoptosis by upregulating Bax and down-regulating survivin in MNU-induced breast cancer,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 9, pp. 3939–3944, 2014.

[66] K. Miyagawa, C. Sakakura, S. Nakashima et al., ”Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis,” Anticancer Research, vol. 26, no. 5b, pp. 3633–3643, 2006.

[67] M. Zhuang, W. Gao, J. Xu, P. Wang, and Y. Shu, ”The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1,” Biochemical and Biophysical Research Communications, vol. 448, no. 3, pp. 315–322, 2014.

[68] R. Ishikawa, Y. Amano, M. Kawakami et al., ”The chimeric transcript RUNX1-GLRX5: a biomarker for good postoperative prognosis in stage IA non-small-cell lung cancer,” Japanese Journal of Clinical Oncology, vol. 46, no. 2, pp. 185–189, 2016.

[69] A. Doll, M. Gonzalez, M. Abal et al., ”An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis,” International Journal of Cancer, vol. 125, no. 2, pp. 257–263, 2009.

[70] N. Ferrari, Z. M. Mohammed, C. Nixon et al., ”Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer,” PLoS One, vol. 9, no. 6, article e100759, 2014.

[71] L. Wang, J. S. Brugge, and K. A. Janes, ”Intersection of FOXO and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 40, pp. E803–E812, 2011.

[72] M. L. Slattery, A. Lundgreen, J. S. Herrick, B. J. Caan, J. D. Potter, and R. K. Wolff, ”Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-beta-signaling pathway,” Carcinogenesis, vol. 32, no. 3, pp. 318–326, 2011.